Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHABET study of alpelisib plus trastuzumab with or without fulvestrant versus trastuzumab plus chemotherapy in PIK3CA-mutated HER2-positive advanced breast cancer
NL-OMON53690Phase 3Withdrawn
- Sponsor
- GEICAM
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alpelisib, trastuzumab and fulvestrant in breast cancer (4 cohorts), sponsored by GEICAM. Primary endpoint: Progression-free survival. Planned start Jun 2022; status: withdrawn.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON53690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53690.